Current Report Filing (8-k)
June 14 2021 - 5:01PM
Edgar (US Regulatory)
0001368514
false
true
0001368514
2021-06-08
2021-06-08
0001368514
us-gaap:CommonStockMember
2021-06-08
2021-06-08
0001368514
ADMA:PreferredSharePurchaseRightsMember
2021-06-08
2021-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 8, 2021
ADMA BIOLOGICS, INC.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-36728
|
56-2590442
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
465 State Route 17, Ramsey, New Jersey
|
07446
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (201) 478-5552
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is
an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
ADMA
|
Nasdaq Global Market
|
Preferred Share Purchase Rights
|
-
|
Nasdaq Global Market
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On June 8, 2021, Dr. James Mond, M.D., Ph.D., Chief
Medical Officer and Chief Scientific Officer, voluntarily resigned from ADMA Biologics, Inc. (the “Company”), effective immediately.
In connection with Dr. Mond’s resignation, the Company and Dr. Mond are negotiating a transition arrangement.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
June 14, 2021
|
ADMA Biologics, Inc.
|
|
|
|
|
|
By:
|
/s/ Brian Lenz
|
|
|
Name:
|
Brian Lenz
|
|
|
Title:
|
Executive Vice President and Chief Financial Officer
|
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024